References
Lawrence RC, Helmick CG, Arnett FC, Deyo RA, Felson DT, Giannini EH et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 41:778–799
Weyand CM, Goronzy JJ (2003) Giant-cell arteritis and polymyalgia rheumatica. Ann Intern Med 139:505–515
van der Veen MJ, Dinant HJ, van Booma-Frankfort C, van Albada-Kuipers GA, Bijlsam JW (1996) Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis? Ann rheum Dis 55:218–223
Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B (2001) Combined treatment of giant-cell arteritis with methotrexat and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 134:106–114
Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM (2001) T cell activation in rheumatoid synovium is B cell dependent. J Immunol 167:4710–4718
Dorner T, Burmester GR (2003) The role of B cells in rheumatoid arthritis: mechanisms and therapeutic targets. Curr Opin Rheumatol 15:246–252
Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, Stevens RM, Shaw T (2004) Efficacy of B-cell targeted therapy with rituximab in patients with rheumatoid arthritis. N Eng J Med 350:2572–2581
Bhatia A, Ell PJ, Edwards JCW (2005) Anti-CD20 monoclonal antibody (rituximab) as an adjunct in the treatment of giant cell arteritis. Ann Rheum Dis 64:1099–1100
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Mayrbaeurl, B., Hinterreiter, M., Burgstaller, S. et al. The first case of a patient with neutropenia and giant-cell arteritis treated with rituximab. Clin Rheumatol 26, 1597–1598 (2007). https://doi.org/10.1007/s10067-007-0684-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10067-007-0684-0